Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020193758 - COMBINATION THERAPY OF ALK-POSITIVE NEOPLASIA

Publication Number WO/2020/193758
Publication Date 01.10.2020
International Application No. PCT/EP2020/058736
International Filing Date 27.03.2020
IPC
A61K 31/439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
Applicants
  • ACADEMISCH MEDISCH CENTRUM [NL]/[NL]
Inventors
  • VERSTEEG, Rogier
Agents
  • DE PAUW, Elmar
Priority Data
19165603.227.03.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION THERAPY OF ALK-POSITIVE NEOPLASIA
(FR) POLYTHÉRAPIE DE LA NÉOPLASIE ALK-POSITIVE
Abstract
(EN)
The invention relates to a pharmaceutical product comprising therapeutically effective amounts of: (a) an ALK inhibitor or an antibody-drug conjugate directed to the ALK receptor, and (b) a NF-related apoptosis-inducing ligand (TRAIL) receptor agonist.
(FR)
L'invention concerne un produit pharmaceutique comprenant des quantités thérapeutiquement efficaces de : (A) un inhibiteur d'ALK ou un conjugué anticorps-médicament dirigé vers le récepteur d'ALK, et (b) un agoniste du récepteur de ligand induisant l'apoptose lié à NF (TRAIL).
Latest bibliographic data on file with the International Bureau